Additionally, the study indicates that TNF inhibitors and abatacept did not exhibit a significant difference in remission rates when compared with placebo.3This finding confirms that biological agents like tocilizumab are effective in improving remission rates in GCA patients compared with control groups. The gene discussed is TNF; the disease is temporal arteritis.